Entasis Therapeutics (NASDAQ:ETTX) Announces Quarterly Earnings Results, Misses Expectations By $0.44 EPS

Entasis Therapeutics (NASDAQ:ETTX) issued its quarterly earnings data on Monday. The company reported ($1.02) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.58) by ($0.44), Fidelity Earnings reports.

NASDAQ:ETTX traded down $0.07 during mid-day trading on Tuesday, hitting $6.93. The stock had a trading volume of 2,628 shares, compared to its average volume of 11,889. The stock has a market capitalization of $91.79 million and a PE ratio of -0.56. The stock’s 50 day moving average is $6.42. Entasis Therapeutics has a 52 week low of $3.97 and a 52 week high of $13.70. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.79 and a quick ratio of 8.79.

Several analysts recently weighed in on the stock. ValuEngine upgraded shares of Entasis Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Zacks Investment Research downgraded shares of Entasis Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, May 20th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $16.50.



Entasis Therapeutics Company Profile

Entasis Therapeutics Holdings, Inc operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin.

Featured Article: Can systematic risk be avoided?

Receive News & Ratings for Entasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.